Biologics News
VONJO (pacritinib), FDA Approved for Treatment of Intermediate or High-risk Myelofibrosis, Available at Biologics by McKesson
CARY, N.C., March 2, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by
PYRUKYND (mitapivat), FDA Approved for Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency, Available Exclusively at Biologics by McKesson
CARY, N.C., March 2, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected
TARPEYO (budesonide) delayed release capsules, FDA Approved to Reduce Proteinuria in IgA Nephropathy, Available Exclusively at Biologics by McKesson
CARY, N.C., Dec. 22, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected
BESREMi (ropeginterferon alfa-2b-njft), FDA Approved for Treatment of Polycythemia Vera, Available at Biologics by McKesson
CARY, N.C., Dec. 6, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was
Newly Approved LIVTENCITY (maribavir) Now Available at Biologics by McKesson
CARY, N.C., Dec. 3, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected
EXKIVITY (mobocertinib), First and Only FDA Approved Oral Treatment of EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., NOVEMBER 3, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been